Read our latest HIV Drug Therapy Glasgow 2026 content (++++)

Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study Free with registration until Nov 19, 2026 https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00148-7/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_hivglasgow26&_hsenc=p2ANqtz--GKBEzW8lbKNdxpPqI3pLeNWKucj7cfs9rrHPxONZYYipZcycdPbdpQC2qCdHv8nH8oG36OIqH6rhP8CZToUcfg0ZOyQ&_hsmi=448348523&utm_content=448348523&utm_source=hs_email Long-acting antibody-based regimens might reduce treatment burden for people living with HIV. We aimed to assess safety, pharmacokinetics, and antiviral activity of TMB-365, a CD4-directed monoclonal antibody, combined with TMB-380, a long-acting broadly neutralising monoclonal antibody targeting gp120 CD4-binding site. SERIES Antiretroviral therapy, adiposity, and cardiometabolic risk in people with HIV Free with registration https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00231-6/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_hivglasgow26&_hsenc=p2ANqtz--yfNAKU-pLsQjfGwTnoYaQ53Mz54ssmVs7-6G_O2JIE1vVE_57j1QwA2pci1z62nbbifPicWyTl9O994a387m1oI8k7A&_hsmi=448348523&utm_content=448348523&utm_source=hs_email Return to health accounts for only part of the weight gain observed with modern antiretroviral therapy (ART). A fuller account requires integrating recovery from HIV-related catabolism, HIV-associated adipose tissue remodelling, withdrawal of weight-suppressive antiretrovirals, possible direct or permissive effects of newer agents, individual susceptibility, and obesogenic environments. Evidence from ART initiation and switch studies, PrEP trials, and mechanistic research in adipose tissue suggests that ART-associated weight gain is heterogeneous rather than a uniform restorative process. Once adiposity is established, ART switching has a limited ability to reverse weight gain, consistent with the biological persistence of acquired adiposity. Future care should move beyond ART manipulation alone and incorporate early monitoring, body-composition assessment, cardiometabolic prevention, lifestyle intervention, and appropriate antiobesity pharmacotherapy Weight management in people with HIV Free with registration https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00229-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_hivglasgow26&_hsenc=p2ANqtz-9HqHYdYVF_MAU9He7oy9aRFg67fN32jhDx8FpGlcBgNlQqY_vhTH137Vb7Dp-WmS5nVvX5jq-LIK9c5ApW5Hdzg8lYLA&_hsmi=448348523&utm_content=448348523&utm_source=hs_email Excess weight gain in people with HIV is now recognised as a common risk associated with the use of guideline-recommended antiretroviral therapy, such that nearly 50% of people with HIV are living with comorbid obesity. Weight gain and clinical obesity exacerbate cardiovascular–kidney–metabolic health complications in this population and chronic weight management strategies that reduce these risks are now an urgent priority. Behavioural interventions can be offered to improve diet and increase physical activity, including increasing protein intake and promoting regular physical activity. Additionally, there is a growing body of evidence to support the use of GLP-1 receptor agonist therapies in people with HIV, along with a historical literature showing the efficacy of tesamorelin; however, there are sparse data to direct the use of other approved obesity management medicines specific to this population. Finally, bariatric surgical interventions are suggested to be safe and efficacious for those with chronic HIV infection and comorbid obesity. This Series paper identifies a range of key evidence gaps and research priorities for obesity management in people with HIV, including a lack of trials of GLP-1 therapies in people with HIV powered to key clinical outcomes, such as major adverse cardiovascular events and body composition endpoints, implementation science to define models of care, and research on the heterogeneities in clinical outcomes of obesity treatment by sex. HIV, obesity, and stigma: lessons for programmes, policy, and practice Free with registration https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00236-5/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_hivglasgow26&_hsenc=p2ANqtz-9d2FIceyi85rQ_VlEiwXkm1pfOBq5ZMAY-DoOHirb9WoWzNPKJwXe_kcw8UtjPOC5QP00LrD57n9Ni6ivqkbxpO0ihQg&_hsmi=448348523&utm_content=448348523&utm_source=hs_email HIV has generated four decades of activism, research, and policy reform that produced measurement tools, theoretical frameworks, and consensus that stigma undermines prevention, delays treatment, and entrenches inequity. Weight stigma follows a strikingly similar pattern, operating through visibility, assumptions of personal control, and moralised concern, and is now recognised as a public health priority in its own right. These two forms of stigma increasingly intersect in the same bodies: antiretroviral therapy, particularly newer regimens, is associated with substantial weight gain, so that people once stigmatised for wasting now risk a second, contradictory stigma for excess weight. This intersection is complex; internalised stigma from either condition can resurface long after apparent resolution, even when viral suppression has been reached or after major weight loss. HIV and obesity differ in diagnostic certainty, visibility, permanence, and the origins of activism and legal protection, which helps explain why HIV stigma reduction remains decades ahead. Applying the Health Stigma and Discrimination Framework to this intersection clarifies shared drivers, facilitators, manifestations, and outcomes. Community leadership, rejection of false prevention-versus-treatment trade-offs, equitable access to pharmacotherapy, and integration of obesity care into existing HIV services offer a practical path towards reducing both stigmas.